Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 12, 2001, Pages 3445-3450

  Hsyu, P H ^a   Schultz Smith, M D ^a   Lillibridge, J H ^a   Lewis, R H ^a   Kerr, B M ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; DIPHENHYDRAMINE; EFAVIRENZ; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MEVINOLIN; NELFINAVIR; PARACETAMOL; PREDNISONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMVASTATIN; STEROID; TRIAMCINOLONE ACETONIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIPODYSTROPHY; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RASH; VIRUS INFECTION; VIRUS INHIBITION;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; DRUG INTERACTIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; NELFINAVIR; PYRROLES; SIMVASTATIN;

EID: 0035185490     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.12.3445-3450.2001     Document Type: Article

References (25)

1. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin
2. FDA warns of potential protease-inhibitor link to hyperglycaemia
3. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
4. HMG-CoA reductase inhibitors and P-glycoprotein modulation
5. Atorvastatin coadministration may increase digoxin concentrations: Inhibition of intestinal P-glycoprotein-mediated secretion
6. Antiretroviral therapy for HIV-1 infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
7. Multiple-dose pharmacokinetics, pharmacodynamics and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy volunteers
8. New-onset diabetes mellitus associated with use of protease inhibitor
9. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus and prior antiretroviral therapy
10. The drug transporter P-glycoprotein limits oral absorption and brain entrance of HIV protease inhibitors
11. Christians. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine
12. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors
13. Visceral abdominal-fat accumulation associated with use of indinavir
14. Changing patterns of mortality across Europe in patients infected with HIV-1
15. Atorvastatin for protease inhibitor-related hyperlipidaemia
16. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
17. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
18. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin
19. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
20. Drug interaction-induced rhabdomyolysis
21. Disorder of fat distribution in HIV infection
22. Impact of combination therapy for HIV infection on inpatient census
23. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of Pglycoprotein
24. Atorvastatin transport in Caco-2 cell model: Contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter
25. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: Structural identification, levels in plasma, and antiviral activities